Steroids vs. NSAIDs in Treating Acute Gout

By Jack Cush, MD | 25 July 2018

Gout, the ancient disease of kings is usually treated with the ancient (and costly) drug colchicine, often without consideration of nonsteroidal antiinflammatory drugs (NSAID) or corticosteroids. A recent metanalysis compared the NSAIDS and steroids and showed that both were equipotent in managing the pain of acute gout, but corticosteroids appear had a more favorable safety profile.

The metanalysis revieweed 6 eligible trials, with a total of 817 gout patients treated with either NSAIDs or corticosteroids and had a followup was 15 days (range 4-30).

By day 7, the pain score was low and not significantly different between the two (SMD -0.09; 95% CI -0.26 to 0.08)

There was no difference in the time to disease resolution, or number of supplementary analgesics used.

However, there was a lower risk of indigestion (RR 0.50, 95% CI 0.27-0.92), nausea (RR 0.25, 95% CI 0.11-0.54), and vomiting (RR 0.11, 95% CI 0.02-0.56) with corticosteroid therapy.

Corticosteroids may be preferred over NSAIDs in managing acute gout as they have less GI adverse events in RCTs.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Ironwood Retreats from the US Gout Market

By Jack Cush, MD | 18 Mar 2019

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

Allopurinol Reduces Cardiovascular Outcomes in Diabetes

By Jack Cush, MD | 28 Feb 2019

A Canadian study has shown that elderly diabetics who take allopurinol have a significant reduction in cardiovascular outcomes.

Hyperuricemia has been shown to be a biomarker for cardiovascular outcomes in multiple disorders. These investigators studied the effect of allopurinol and mortality on CV outcomes in a population-based retrospective cohort study from Ontario, Canada.

[...]

FDA Slaps a Boxed Warning on Febuxostat for CV Risk

By Jack Cush, MD | 25 Feb 2019

The U.S. Food and Drug Administration (FDA) has reviewed data from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial and concluded there is an increased risk of death with Uloric (febuxostat) compared with allopurinol, and has added this as a boxed warning to the drug’s product label.

[...]

U.S. Gout Rates Remain Steady, but Substantial

By MedPage Today | 21 Jan 2019

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

[...]

Febuxostat Gets Reprieve from FDA Advisory Panel

By Jack Cush, MD | 16 Jan 2019

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study.

The Vote

You are here